{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:13:44Z","timestamp":1790399624628,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.ejphar.2015.04.040","type":"journal-article","created":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T05:01:15Z","timestamp":1430629275000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A"],"prefix":"10.1016","volume":"761","author":[{"given":"John P.","family":"Redrobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars K.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus T.","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bundgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.04.040_bib1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","article-title":"Memory impairment in schizophrenia: a meta-analysis","volume":"156","author":"Aleman","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.04.040_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bmcl.2012.11.077","article-title":"Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2\/phosphodiesterase 10 (PDE2\/PDE10) inhibitors","volume":"23","author":"Andr\u00e9s","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2015.04.040_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2015.04.040_bib4","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2174\/138161206777698855","article-title":"Improving memory: a role for phosphodiesterases","volume":"12","author":"Blokland","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2015.04.040_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","article-title":"Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance","volume":"47","author":"Boess","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-1119(94)90155-4","article-title":"Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases","volume":"149","author":"Bolger","year":"1994","journal-title":"Gene"},{"key":"10.1016\/j.ejphar.2015.04.040_bib7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0028-3932(93)90070-G","article-title":"Memory in schizophrenia: what is impaired and what is preserved?","volume":"31","author":"Clare","year":"1993","journal-title":"Neuropsychologia"},{"key":"10.1016\/j.ejphar.2015.04.040_bib8","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.20-23-08853.2000","article-title":"Impaired recognition memory in rats after damage to the hippocampus","volume":"20","author":"Clark","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2015.04.040_bib9","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.bmcl.2014.06.028","article-title":"Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part II","volume":"24","author":"Das","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2015.04.040_bib10","doi-asserted-by":"crossref","unstructured":"DeMartinis, N., Banerjee, A., Kumar, V., Boyer, S., Schmidt, C.J., Arrojo, S. 2012. Results of a Phase 2A Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. Poster 212, Presented at the Society for Biological Psychiatry 2012 Annual Meeting. Philadelphia, PA.","DOI":"10.1016\/S0920-9964(12)70783-1"},{"key":"10.1016\/j.ejphar.2015.04.040_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioural data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2015.04.040_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/schbul\/17.2.289","article-title":"New antipsychotics: classification, efficacy, and adverse effects","volume":"17","author":"Gerlach","year":"1991","journal-title":"Schizophr. Bull."},{"issue":"Suppl 2","key":"10.1016\/j.ejphar.2015.04.040_bib14","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs","volume":"35","author":"Gobira","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.ejphar.2015.04.040_bib15","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1016\/j.bmcl.2013.10.014","article-title":"PDE2 inhibition: potential for the treatment of cognitive disorders","volume":"23","author":"Gomez","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejphar.2015.04.040_bib16","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.04.040_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1742-7843.2009.00517.x","article-title":"Active-site concentrations of chemicals \u2013 are they a better predictor of effect than plasma\/organ\/tissue concentrations?","volume":"106","author":"Hammarlund-Udenaes","year":"2010","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2015.04.040_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.euroneuro.2007.08.002","article-title":"Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice","volume":"18","author":"Hebb","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2015.04.040_bib20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0006-3223(00)00919-7","article-title":"Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia","volume":"48","author":"Heckers","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.04.040_bib21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","article-title":"Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability","volume":"120","author":"Hoffman","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib23","unstructured":"J\u00f8rgensen, M., Bruun, A.T., Rasmussen, L.K., Larsen, M, 2013. Preparation of substitued triazolopyrazines as PDE2A and PDE10A inhibitors useful for treating neurological and psychiatric disorders. From PCT Int. Appl. WO20130334755 A1 20130314."},{"key":"10.1016\/j.ejphar.2015.04.040_bib25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0079-6123(09)17908-6","article-title":"Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals","volume":"179","author":"Kelly","year":"2009","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejphar.2015.04.040_bib26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib27","doi-asserted-by":"crossref","first-page":"12375","DOI":"10.1073\/pnas.220398097","article-title":"The visual paired-comparison task as a measure of declarative memory","volume":"97","author":"Manns","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2015.04.040_bib28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fpsyt.2010.00146","article-title":"Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia","volume":"1","author":"Redrobe","year":"2010","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.04.040_bib29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2593-9","article-title":"Negative modulation of GABAA \u03b15 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats","volume":"221","author":"Redrobe","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib30","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1007\/s00213-014-3492-7","article-title":"In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia","volume":"231","author":"Redrobe","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Reneerkens","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2015.04.040_bib32","doi-asserted-by":"crossref","first-page":"18683","DOI":"10.1016\/S0021-9258(19)37015-2","article-title":"A polymerase chain reaction strategy to identify and clone cyclic nucleotide phosphodiesterase cDNAs. Molecular cloning of the cDNA encoding the 63-kDa calmodulin-dependent phosphodiesterase","volume":"267","author":"Repaske","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2015.04.040_bib33","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","article-title":"Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer\u05f3s disease human brains","volume":"25","author":"Reyes-Irisarri","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2015.04.040_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2015.04.040_bib35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.ejphar.2015.04.040_bib36","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1471-4159.2007.05152.x","article-title":"Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2","volume":"105","author":"Sano","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2015.04.040_bib37","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2015.04.040_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.neuropharm.2007.10.009","article-title":"Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57\/Bl6N congenic background","volume":"54","author":"Siuciak","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2015.04.040_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","article-title":"The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey","volume":"64","author":"Smith","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2015.04.040_bib43","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/jpet.108.146944","article-title":"Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission","volume":"328","author":"Sotty","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.04.040_bib44","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1369\/jhc.2009.953471","article-title":"Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species","volume":"57","author":"Stephenson","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2015.04.040_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","article-title":"The distribution of phosphodiesterase 2A in the rat brain","volume":"226","author":"Stephenson","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2015.04.040_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archpsyc.59.2.146","article-title":"Visual perceptual and working memory impairments in schizophrenia","volume":"59","author":"Tek","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.04.040_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2008.10.027","article-title":"Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion","volume":"600","author":"van Donkelaar","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.04.040_bib48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/cne.10955","article-title":"mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain","volume":"467","author":"van Staveren","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ejphar.2015.04.040_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","article-title":"Conditioned avoidance response in the development of new antipsychotics","volume":"16","author":"Wadenberg","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejphar.2015.04.040_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915003994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915003994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T01:15:44Z","timestamp":1691630144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915003994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":46,"alternative-id":["S0014299915003994"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.04.040","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.04.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}